Welcome to use AbleSci to get your papers. Our English Version is under development. You can temporarily use Google to translate AbleSci. Quite easy! Thank you!

发布文献求助

贰雯

Lv1

68 积分 2023-05-17 加入

最近求助
最近应助
互助留言

Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus 12天前 已完结
High-dose subcutaneous Administration of Biologics: Overcoming barriers through formulation and device innovation 21天前 已完结
Personalizing adjuvant therapy for patients with colorectal cancer 1个月前 已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries 1个月前 已完结
Cancer statistics in China and United States, 2022: profiles, trends, and determinants 1个月前 已完结
How I Read a Clinical Trial Report? A Primer for Busy Clinicians 1个月前 已关闭
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China 1个月前 已完结
ESPnet2 pretrained model, Emiru Tsunoo/aishell_asr_train_asr_streaming_transformer_raw_zh_char_sp_valid.acc.ave, fs=16k, lang=zh 2个月前 已完结
小核酸药物非临床特点和药理毒理评价策略 4个月前 已完结
The fickle CHO: a review of the causes, implications, and potential alleviation of the CHO cell line instability problem 7个月前 已完结

没有进行任何应助

没有进行任何互助留言

最近帖子
最近评论

没有发布任何帖子

没有发布任何评论

Copyright © 2020-2026 AbleSci.COM, 科研通, All Right Reserved

科研通是非营利科研互助平台，不忘初心，为科研助力

本站互助的所有文件仅供个人学习研究用，禁止任何人把求助的所得文献进行盈利或传播

皖ICP备2024041134号-1

皖公网安备34019202002308

科研通【文献互助QQ群】：如果您有特殊求助，或发布求助超过24小时未得到应助，可加群求助，群号：821889395【点击一键加群】

科研通【志愿服务QQ群】：如果您热爱文献互助，有热心愿意为更多人服务，请加入小伙伴群，点击申请加入

关注微信服务号

科研通